Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 182

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 182
---
Officer of Ark Biosciences from 2014 until 2020. In addition, he held a teaching and clinical post at the Royal Free and University College
Medical School in London, United Kingdom, Academic Centre for Travel Medicine and Vaccines, World Health Organization Collaborating Center,
appointed in 2008. He has been editor of the journal Travel Medicine and Infectious Disease since its foundation in 2003. Dr. Toovey
has authored over 100 publications in peer reviewed medical journals, contributed to a number of textbooks and has presented at over
50 scientific meetings. Dr. Toovey received his PhD from the University of Ghent. The Board concluded that Dr. Toovey’s background
and leadership experiences in the pharmaceutical industry and academia qualify him to be a member of the Board.

Paul Field is one of our directors
since July 11, 2023. Paul has over 30 years of business development experience across a range of disease areas, and a deep network in
the global biopharmaceutical industry. He is currently a corporate advisor at Imunexus since 2020, Marinova since 2018, and GARDP (Switzerland)
since 2018. He was until recently the Australian representative of FIND (Switzerland) from 2018 to 2021 and a business development advisor
to the drug discovery company Biocurate from 2018 to 2020. Paul was previously the life sciences specialist at Austrade from 2014 to
2018, the Australian Government’s investment promotion agency, where he facilitated foreign direct investment into Australian research
in neglected tropical diseases, infectious diseases, autoimmune diseases, cancer and other therapeutic areas. Paul was the founder and
Executive Chairman of Bio-Link from 2005 to 2014, a privately owned biotechnology business development company. His work at Bio-Link
involved the commercialization of discovery, pre-clinical and early-stage clinical programs undertaken by Australian biotech companies
and medical research institutions. Paul has served on a number of Boards of Directors, and he is a Fellow of the Australian Institute
of Company Directors. The Board concluded that Mr. Field’s background and leadership experiences in the biotechnology industry
qualify him to be a member of the Board.

62

Significant Employees

We are a virtually managed pharmaceutical company
for which the significant employees are its officers.

Code of Ethics

Our Board has adopted a written code of business
conduct and ethics (“Code”) that applies